• Member of the Board of Directors : French Society for Bone and Mineral Research
• Member of the Board of Directors : IESF Auvergne (co-chair of the training module “PhD in Business”)
• Member of the Editorial Board of Nutrients (IF2022 : 5.9 / Q1)
• Co-founder and CSO of ClinicnCell SAS Ex vivo Clinical trials

ECREIN

Je développe des approches nutritionnelles innovantes, translationnelles et collaboratives ciblant de nouvelles voies impliquées dans le dysfonctionnement de l’appareil locomoteur (notamment les tissus ostéo-articulaires) pour préserver la mobilité et améliorer l'espérance de vie en bonne santé. Je suis également co-fondateur de la start-up Clinic’n’Cell qui propose une innovation clinique ex vivo. Cette nouvelle approche associant métabolisme humain et biologie cellulaire fournit des données humaines robustes concernant les bénéfices santé d'un produit de manière plus rapide, plus abordable et plus mécanistique (mode d'action chez l'homme) que tout essai clinique conventionnel. Utilisant les métabolites humains (bioactifs circulants et biodisponibles) cette approche est plus physiologique que n'importe quel test in vitro. Elle permet aussi de s’affranchir de l’expérimentation animale.

I develop innovative, translational and collaborative nutritional approaches targeting new pathways involved in the dysfunction of the musculoskeletal system (notably osteoarticular tissues) to preserve mobility and improve healthy life expectancy. I am also co-founder of the start-up Clinic’n’Cell which offers ex vivo clinical innovation. This new approach combining human metabolism and cell biology provides robust human data on the health benefits of a product in a faster, more affordable and more mechanistic way (mode of action in humans) than any conventional clinical trial. Using human metabolites (circulating and bioavailable bioactives), this approach is more physiological than any in vitro test. It also allows us to avoid animal experimentation.

Dr. Yohann Wittrant; Senior research scientist at INRAE since 2008 (Human Nutrition Unit).  Training: PhD in Cellular and Molecular Biology at INSERM (2005); HDR (accreditation to supervise research) in 2009, Clermont Auvergne University. Post-doctoral position University of Texas Health Science Center at San Antonio, on a NIH grant in 2006 and 2007. Research fields: nutrition and osteo-articular functions; cell biology; nutrient based-biomaterials; clinical trial; human health. Awarded by INRAE in 2013 and 2017 for outstanding scientific contribution. Board of Directors of French Society for Bone and Mineral Research since 2015. Business activities: Co-founder of Clinic’n’Cell SAS (ex vivo clinical trials) since 2020. Winner of the NutraIngredients Awards Europe as the “start-up of the year 2022”.

Publications majeures

Targeting the gut to prevent and counteract metabolic disorders and pathologies during aging. Milenkovic D, Capel F, Combaret L, Comte B, Dardevet D, Evrard B, Guillet C, Monfoulet LE, Pinel A, Polakof S, Pujos-Guillot E, Rémond D, Wittrant Y, Savary-Auzeloux I.Crit Rev Food Sci Nutr. 2023;63(32):11185-11210.

Metabolic and Anti-Inflammatory Protective Properties of Human Enriched Serum Following Artichoke Leaf Extract Absorption: Results from an Innovative Ex Vivo Clinical Trial. Wauquier F, Boutin-Wittrant L, Viret A, Guilhaudis L, Oulyadi H, Bourafai-Aziez A, Charpentier G, Rousselot G, Cassin E, Descamps S, Roux V, Macian N, Pickering G, Wittrant Y.Nutrients. 2021 Jul 30;13(8):2653.

Chondroprotective Properties of Human-Enriched Serum Following Polyphenol Extract Absorption: Results from an Exploratory Clinical Trial. Wauquier F, Mevel E, Krisa S, Richard T, Valls J, Hornedo-Ortega R, Granel H, Boutin-Wittrant L, Urban N, Berger J, Descamps S, Guicheux J, Vinatier CS, Beck L, Meunier N, Blot A, Wittrant Y.Nutrients. 2019 Dec 16;11(12):3071.

Pros and cons of fatty acids in bone biology. Wauquier F, Léotoing L, Philippe C, Spilmont M, Coxam V, Wittrant Y.Prog Lipid Res. 2015 Apr;58:121-45

The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. Wauquier F, Philippe C, Léotoing L, Mercier S, Davicco MJ, Lebecque P, Guicheux J, Pilet P, Miot-Noirault E, Poitout V, Alquier T, Coxam V, Wittrant Y.J Biol Chem. 2013 Mar 1;288(9):6542-51.

Autres liens : 

LinkedIn